Jeffrey Eisele - Jan 13, 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Stock symbol
APLS
Transactions as of
Jan 13, 2025
Transactions value $
-$7,577
Form type
4
Date filed
1/14/2025, 04:15 PM
Previous filing
Dec 27, 2024
Next filing
Jan 23, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$7.58K -264 -0.46% $28.70 56.9K Jan 13, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025.